Home / Health / Novartis Heart Drug Fails in Major Trial

Novartis Heart Drug Fails in Major Trial

5 Sep

Summary

Novartis drug pelacarsen did not reduce heart attack or stroke risk.
The trial was a final-stage test of a new cardiovascular prevention method.
This outcome represents a significant setback for the experimental treatment.

A promising drug from Novartis AG, pelacarsen, has failed to meet its primary endpoint in a pivotal final-stage trial. The experimental treatment, intended as a monthly injection to prevent cardiovascular disease, did not show a reduction in the risk of heart attacks and strokes.

This development marks a significant setback for Novartis and represents a major disappointment for a new strategy aimed at combating cardiovascular conditions. The failure of pelacarsen raises questions about the future of this particular therapeutic approach.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.